 ROCKVILLE, Md., Feb. 22, 2022 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022. 